BioSpace News Archive

Centessa Pharmaceuticals announced that Antoine Yver, M.D., M.Sc., has been appointed as Chief Medical Officer.

Serious runners and casual walkers alike are invited to join a month-long Get Your Rear in Gear® - Madison run/walk virtual event during May to raise money and awareness for colorectal cancer screening efforts.

Attralus, backed by venBio Partners, recruits new leadership team to support advancement of its pipeline to bring transformational pan-amyloid removal therapies to the systemic amyloidosis field

Dynavax Technologies Corporation (“Dynavax”) (Nasdaq: DVAX) today announced that it intends to offer, subject to market conditions and other factors, $200 million aggregate principal amount of convertible senior notes due 2026 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers

Preclinical data provide quantitative evidence of miRARE’s ability to exhibit genotype-dependent regulation of MECP2 gene expression across different brain regions in both wild type and knockout mouse models of Rett syndrome

Conformis, Inc. (NASDAQ:CFMS) today announced 510(k) clearance by the U.S. Food and Drug Administration for the Company’s Identity Imprint Knee Replacement System. Identity Imprint is a new total knee replacement system, available in both cruciate retaining (CR) and posterior stabilized (PS) versions, that expands the range of options open to Conformis’ orthopedic surgeon customers and their patients. Whereas the Conformis iTotal® Identity k

Elekta invites analysts and investors to a presentation of the fiscal year 2020/21 at 10:00 a.m. CEST on May 28.

Smart Immune SAS, a T cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus in a dish” technology to develop proprietary allogeneic T cell progenitor product SMART 101 for rapid reconstitution of T cell immunity, announced that its Investigational New Drug for Acute lymphocytic leukemia and Acute myelocytic leukemia has been accepted by the FDA.

BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that it is initiating expansion of its Melville, New York based research laboratories to include capabilities for the clinical production of the Company’s pipeline of clinical and investigational cell therapy candidates.

Strong balance sheet of ~$325 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2024